CheukMan Cherie Au

CheukMan Cherie Au

Auto-generated profile, based on publicly available information

CheukMan Cherie Au

Department of Medicine, Weill Cornell Medical College

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
PBPriya Bhardwaj
Priya Bhardwaj
CACheukMan C. Au
CheukMan C. Au
ABAlberto Benito-Martin
Alberto Benito-Martin
HLHeta Ladumor
Heta Ladumor
SOSofya Oshchepkova
Sofya Oshchepkova
KBKristy A. Brown
Kristy A. Brown

24 July 2014 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MDMaria M. Docanto
Maria M. Docanto
FYFangyuan Yang
Fangyuan Yang
BCBrid Callaghan
Brid Callaghan
CACheukMan C. Au
CheukMan C. Au
RRRahini Ragavan
Rahini Ragavan
KBKristy A. Brown
Kristy A. Brown

1 June 2017 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
CACheukMan C. Au
CheukMan C. Au
MDMaria M. Docanto
Maria M. Docanto
HZHeba Zahid
Heba Zahid
FRFrancesca-Maria Raffaelli
Francesca-Maria Raffaelli
RFRichard L. Ferrero
Richard L. Ferrero
KBKristy A. Brown
Kristy A. Brown

18 July 2022 in eLife
Verified
Journal Article
Open access
SKSeaho Kim
Seaho Kim
CACheukMan C Au
CheukMan C Au
MJMohd Azrin Bin Jamalruddin
Mohd Azrin Bin Jamalruddin
NANaira Essam Abou-Ghali
Naira Essam Abou-Ghali
EMEiman Mukhtar
Eiman Mukhtar
PGParaskevi Giannakakou
Paraskevi Giannakakou
Expression of the AR splice variant, androgen receptor variant 7 (AR-V7), in prostate cancer is correlated with poor patient survival and resistance to AR targeted therapies and taxanes. Currently, there is no specific inhibitor of AR-V7, while the molecular mechanisms regulating its biological function are not well elucidated. Here, we report that AR-V7 has unique biological features that functionally differentiate it from canonical AR-fl or from the second most prevalent variant, AR-v567. First, AR-V7 exhibits fast nuclear import kinetics via a pathway distinct from the nuclear localization signal dependent importin-α/β pathway used by AR-fl and AR-v567. We also show that the dimerization box domain, known to mediate AR dimerization and transactivation, is required for AR-V7 nuclear import but not for AR-fl. Once in the nucleus, AR-V7 is transcriptionally active, yet exhibits unusually high intranuclear mobility and transient chromatin interactions, unlike the stable chromatin association of liganded AR-fl. The high intranuclear mobility of AR-V7 together with its high transcriptional output, suggest a Hit-and-Run mode of transcription. Our findings reveal unique mechanisms regulating AR-V7 activity, offering the opportunity to develop selective therapeutic interventions.

9 January 2017 in Frontiers in Oncology
Verified
Journal Article
Open access
CACheukMan Cherie Au
CheukMan Cherie Au
JFJohn Furness
John Furness
KBKristy A. Brown
Kristy A. Brown
Local and systemic factors have been shown to drive the growth of breast cancer cells in postmenopausal obese women, who have increased risk of estrogen receptor (ER)-positive breast cancer. Estrogens, produced locally in the breast fat by the enzyme aromatase, have an important role in promoting cancer cell proliferation. Ghrelin, a 28-amino acid peptide hormone, may also influence cancer growth. This peptide is produced in the stomach and acts centrally to regulate appetite and growth hormone release. Circulating levels of ghrelin, and its unacylated form, des-acyl ghrelin, are almost always inversely correlated with obesity, and these peptide hormones have recently been shown to inhibit adipose tissue aromatase expression. Ghrelin and des-acyl ghrelin have also been shown to be produced by some tumor cells and influence tumor growth. The ghrelin/des-acyl ghrelin-cancer axis is complex, one reason being that tumor cells have been shown to express splice variants of ghrelin, and ghrelin and des-acyl ghrelin might act at receptors other than the cognate ghrelin receptor, GHSR1a, in tumors. Effects of ghrelin and des-acyl ghrelin on energy homeostasis may also affect tumor development and growth. This review will summarize our current understanding of the role of ghrelin and des-acyl ghrelin in hormone-dependent cancers, breast cancer in particular.

1 April 2026 in Cancer Discovery
Verified
Journal Article
Closed access
CACheukMan Cherie Au
CheukMan Cherie Au
DADaniel D. Azorín
Daniel D. Azorín
JCJian Carrot-Zhang
Jian Carrot-Zhang
SCSteven M. Corsello
Steven M. Corsello
ACAlvaro Curiel-Garcia
Alvaro Curiel-Garcia
DZDaniel J. Zabransky
Daniel J. Zabransky